Bevacizumab and Irinotecan in Treating Patients With Recurrent or Refractory Gliomas

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Duke University
ClinicalTrials.gov Identifier:
NCT00268359
First received: December 20, 2005
Last updated: July 18, 2014
Last verified: February 2013